Meeting
2018 ASCO Annual Meeting
Next generation sequencing (NGS) based mutation profiling and heterogeneity of resistance mechanisms to AZD9291.
Authors
Jun Zhao
Beijing Cancer Hospital, Beijing, China
Jun Zhao , Rongrong Chen , Gen Lin , Xinghao Ai , Wang Sheng , Youxin Ji , Zaiwen Fan , Liyun Miao , Lingjun Zhu , Qiong Zhao , Renhua Guo , Xin Yi , Xuefeng Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9068)
DOI
10.1200/JCO.2018.36.15_suppl.9068
Abstract #
9068
Poster Bd #
391
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).
First Author: Ji-Youn Han
Poster
2017 ASCO Annual Meeting
Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.
First Author: Nicolas Marie Guibert
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2021 ASCO Annual Meeting
Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).
First Author: Pasi A. Janne